Schizophrenia Biomarker Services
Schizophrenia
Service OfferingActive
Key Facts
About The Siesta Group
The Siesta Group is a Vienna-based, neuroscience-focused service provider that empowers CNS drug development through advanced analysis of EEG, sleep, and activity data. Leveraging over 20 years of experience, proprietary AI-powered analysis tools, and a strong scientific network, the company helps sponsors identify biomarkers and endpoints for conditions ranging from sleep disorders to neurodegenerative diseases. It operates as a trusted partner to over 30 leading sponsors and CROs, offering a full suite of clinical trial services from feasibility to data visualization, all while maintaining rigorous compliance standards.
View full company profileTherapeutic Areas
Other Schizophrenia Drugs
| Drug | Company | Phase |
|---|---|---|
| DB103 (Pomaglumetad) | Denovo Biopharma | Phase 2b/3 |
| ZZ6398 | Zhongze Therapeutics | Phase 1/2 |
| RBP-7000 (PERSERIS®) | Indivior | Marketed |
| Undisclosed Programs | johnson-and-johnson-innovative-medicine | Pipeline |
| Schizophrenia Candidate | Teva | Phase 3 |
| Schizophrenia Model Service | NeuroProof | Pre-clinical |
| LYN-005 (Nortiva) | Lyndra | Phase 3 |
| TerXT | Terran Biosciences | Late-stage (Pre-Phase 3) |
| Undisclosed Program | Curemark | Preclinical |
| Schizophrenia Intermediate | OFD Biopharma | Proof of concept |
| Schizophrenia | Keltic Pharma Therapeutics | Pre-clinical |
| AVAT-031 | Avata Biosciences | Discovery |